What is piggyBac? GenomeFrontier Therapeutics' Non-Viral CAR-T Therapy Moves to Clinical Trials in Taiwan!

Securing IND approval in Taiwan is notoriously more challenging than in the U.S.

In 2006, Dr. Sareina Chiung-Yuan Wu, founder of GenomeFrontier Therapeutics, discovered the potential of piggyBac as a gene vector. This breakthrough led to the founding of GenomeFrontier in 2018. Now, after nearly two decades of innovation, the company is advancing to the clinical stage with its non-viral vector CAR-T therapy.

 "Since my student days, I have always pursued the latest frontiers."

True to Dr. Wu’s pioneering spirit, GenomeFrontier continues to push the boundaries of cell and gene therapy, striving to bring Taiwan’s cutting-edge technology to the world and transform the future of disease treatment.

Read more: http://bit.ly/v94company1

Follow Globalbio for biotech updates!